Epstein Barr Virus Market, By Test (Complete Blood Count Test, Monospot test and Others), By Application (Mononucleosis, Gastric Carcinoma, Multiple Sclerosis and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI472921 | Publish Date: May 2024 | No. of Pages: 168

Global Epstein Barr Virus Market Overview

Epstein Barr Virus Market accounted for US$ 1.54 billion in 2020 and is estimated to be US$ 2.48 billion by 2030 and is anticipated to register a CAGR of 5.3%.

Epstein-Barr virus is the most prevalent form of virus in humans, and it is one of eight varieties of human herpes viruses. The Epstein–Barr virus (EBV) is the most common cause of infectious mononucleosis, which has been linked to a variety of cancers, including gastric carcinoma, nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin lymphoma, lymphomas in immunocompromised people, and multiple sclerosis. The Epstein–Barr virus has been associated to a variety of lymphatic malignancies and lupus in numerous studies. The symptoms of this condition are similar to those of other illnesses, making detection challenging. Fatigue, fever, an inflamed throat, and an enlarged liver are all symptoms of EBV infection. Antibodies to the Epstein-Barr virus can be detected in a blood test. The presence of viral gene expression in every tumour cell, as well as proof that EBV is clonal (or oligoclonal) in tumor cells, are all requirements for EBV association with cancer. 

Impact of Covid-19 pandemic on market

A novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for an outbreak of Coronavirus Disease 2019 (COVID-19) in Wuhan, China, since December 2019. SARS-CoV-2 was extremely contagious and spread quickly. According to COVID-19 patients' laboratory results, some of them tested positive for Epstein-Barr virus (EBV) viral capsid antigen (VCA) IgM antibodies. Despite the fact that EBV infection affects up to 90% of the adult population, most immunocompetent patients show no clinical symptoms following infection . It can, however, be reactivated and spread in immunocompromised people, resulting in death. Burkitt lymphoma, nasopharyngeal carcinomas, and T-cell/NK lymphoma have all been linked to EBV infection, as have autoimmune illnesses including systemic lupus erythematosus (SLE) and multiple sclerosis. The pathology report of a COVID-19 dead patient recently showed that T cells were overactivated, which led to significant immunological damage in COVID-19 patients to some extent. Furthermore, COVID-19 and EBV-induced infectious mononucleosis (IM) share symptoms such as fever, tiredness, myalgia, anorexia, and sore throat, indicating a possible link.

Global Epstein Barr Virus Market Dynamics

Growth in business operations by emerging and small sized players

Several universities are frequently engaged in research and development for the production of innovative monovaccines. For example, the University of Kansas School of Engineering and School of Pharmacy has been researching the genetics of human immune responses in order to develop a powerful Epstein–Barr virus (EBV) vaccine since 2017. The global Epstein–Barr virus vaccine market is likely to be driven by rising research activity by various organizations for the development of innovative EBV vaccines. The market is being driven by advances in serological testing for Epstein-Barr virus infection. Furthermore, the market is being driven by the demand for innovative medicines to treat Epstein-Barr virus infections. Growing public awareness of therapeutic options, as well as technical advancements, are all propelling the market forward.

Global Epstein Barr Virus Market Segmentation

Epstein Barr virus market is segmented based on test, application, and region.

On the basis of Test, the Epstein barr virus market is segmented into Complete Blood Count Test, Monospot test and Others. Based on Application, the target market is segmented mononucleosis, gastric carcinoma, multiple sclerosis, and others.

Regional Insights:

On region the Epstein Barr virus market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. During the forecast period, North America is expected to have a significant proportion of the global Epstein–Barr virus vaccines market. This is  expected to grow due to a high rate of EBV infection, high diagnosis rate, well-developed health-care infrastructure, and a big number of R&D activities. The market for Epstein–Barr virus vaccines in Asia and the Middle East is expected to grow due to an increase in the incidence of chronic diseases, government involvement in improving health care facilities, and an increase in disposable income in these regions.

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Test- Complete Blood Count Test, Monospot test and Others

By Application–Mononucleosis, Gastric carcinoma, Multiple sclerosis,  and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Epstein barr virus market report based on test, application, and region.

Epstein Barr Virus Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Global Epstein Barr Virus Market Key Players

The key players operating in the global Epstein Barr virus market includes Abbott, Bio-Rad Laboratories, Inc., Danaher Corporation, Cardinal Health Inc., Thermo Fischer Scientific Inc., and Others.

Global Epstein Barr Virus Market Company Profile

  • Abott*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Cardinal Health Inc.
  • Thermo Fischer Scientific Inc.
  • Others

 “*” marked represents similar segmentation in other categories in the respective section.

FAQs

Epstein Barr virus market is segmented based on test, application, and region.

Epstein–Barr virus market is likely to be driven by rising research activity by various organizations for the development of innovative EBV vaccines.

North America is expected to have a significant proportion of the global Epstein–Barr virus vaccines market. This is expected to grow due to a high rate of EBV infection, high diagnosis rate, well-developed health-care infrastructure, and a big number of R&D activities

The majority of institutions are working on Epstein–Barr virus vaccines and finding new research, but with only a few private players investing in new Epstein–Barr virus vaccines. .